All In Biotech

Drug Trial Radar · NCT05642546

First-in-Human (FIH) Clinical Study of NM8074 in Healthy Adult Volunteers

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of NM8074 Administered Intravenously to Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Dec 8, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

40

Actual

Start

Aug 12, 2020

Primary completion

Jun 15, 2022

Study completion Jun 15, 2022

Sponsor

Lead sponsor
NovelMed TherapeuticsIndustry
Sponsor type
Industry
Collaborators
Labcorp Corporation of America Holdings, Inc
First posted
Dec 8, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase 1 randomized, double-blind, placebo-controlled, single administration, sequential cohort with sentinel dosing, dose escalation study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of NM8074 in healthy subjects. This study will include 5 cohorts, with each cohort consisting of a total of 8 healthy subjects, including both males and females, randomized in a 3:1 ratio of NM8074 to placebo (6 subjects assigned to NM8074 and 2 subjects assigned to placebo).

Conditions

  • Healthy

Interventions

  • NM8074Drug

    Novel, recombinant, humanized monoclonal antibody that selectively binds to human Factor Bb with high affinity and blocks the formation of Alternative Pathway (AP) driven C3 and C5 convertases

  • PlaceboDrug

    Saline Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Monitoring of Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Up to 71 days post-dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Covance Clinical Unit

    Dallas, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.